Marina Takes Aim at Big Pharma Partnerships with RNAi Alternatives

"Diversity is critical to success,” Marina President and CEO Michael French said this week. Just as “no one single delivery technology is going to solve everything, no one single modality approach in the RNA and RNAi sector" is going to be the sole answer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.